Global Market Study on Anticancer Drugs

Sep 2018| PMR958A| Persistence Market Research

Report Highlights

Report Description

This Persistence Market Research (PMR) report examines the global anticancer drugs market for the period 2013–2026. The primary objective of the report is to offer insights into market opportunities for anticancer drugs and developments in the anticancer drugs market.

The global anticancer drugs market is expected to yield impressive gains owing to the increasing prevalence of cancer. According to the World Health Organization, the number of global cancer deaths is projected to increase by 45% by 2030, with 70% of the cancer deaths expected to occur in low and middle income countries. Mortality from cancer is projected to reach over 13 million in 2030, while, the number of new cancer cases is expected to increase more than 80% in low-income countries, almost double the 40% rate anticipated in high-income countries by 2030.

The global anticancer drugs market has witnessed a paradigmatic shift from administering highly toxic drugs to targeted personalized therapy with lower side effects. There is an upsurge in adoption of biologics especially monoclonal antibodies. New drug development has achieved high importance owing to emergence of difficulties to treat cancers such as small cell lung cancer. The increase in the number of clinical trials coupled with the growing research and development expenditures has resulted in an buildup of impressive new drug pipeline, which is expected to confer large future market equity for the global anticancer drugs market.

The improvement in the survival rate of cancers, e.g., prostrate and breast, is expected to increase the adoption of cancer treatment, which consequently is expected to drive the growth of the global anticancer drugs market. However, lung cancer is expected to be the single large and most attractive market opportunity owing to its large diseases prevalence and poor patient survival rates especially in the advanced stages. The market for global anticancer drugs is also being driven by the advancements in diagnostics and the growing screening rates. Early detection has been the historical holy grail of cancer treatment owing to its impact on survival rates. Advancements and availability of diagnostics such as computed tomography, nuclear medicine are also expected to fuel revenue growth of the anticancer drugs market.

The Global Anticancer Drugs Market has been Segmented Based on:

Drug Class
Indications
Distribution Channels
Regions

The report analyzes the global anticancer drugs market in terms of value (US$ Mn). The report begins with the market definition and explaining different types of drug class and indications for their use. This section also explains the prevalence of different types of cancers across the key regions. The market view point section includes PMR’s analysis on the key trends, drivers, opportunities, trends and macro factors influencing the global anticancer drugs market. Opportunity analysis provided in the section allows clients to better equip with crystal clear decision-making insights.

The report analyzes the anticancer drugs market based on regions and presents the forecast in terms of value (US$ Mn) for the next 08 years. The regions covered in the report include:

North America
Latin America
Europe
Asia-Pacific Excluding Japan
Middle East & Africa
Japan

Each of the section analyzes the regional market by drug class, indications and distribution channel and region. The regional introductory section provides key insights on the market dynamics for each region. The section is mainly designed to provide current scenario of the anticancer drugs market and forecast for 2018–2026. The representative market participants section gives the list of companies operating in each region, competitive landscape and intensity map of their presence in each region.

To arrive at the market value, we have used our in-house proprietary model to estimate the anticancer drugs market value. We have adopted bottom-up approach to forecast the anticancer drugs market. Weighted average selling price is considered to estimate the market value of various drug class mentioned in the scope of the report. The country price is captured with the local currency. The local currency figures are then converted to US$ to offer forecasts in a consistent currency standard. Furthermore, PMR has also considered the latest annual exchange rate to reflect the impact of the most recent economic conditions of a country. Prices considered in the models are standardized based on the average of various drug class.

The revenue forecast presented in the report provides total revenue of the currently available anticancer drugs over 2013–2026. In addition, we have taken into consideration the year-on-year growth to understand the predictability of the market and to identify the right growth opportunities in the global market.

In the next section of the report, the ‘Competitive Landscape’ is included to provide report audiences with a dashboard view and to access the key differentiators among the competitor firms. The market structure analysis provides tier-wise breakdown of the total market revenue. The section also provides company share analysis and brand share analysis for the key market players. This section is primarily designed to provide clients with an objective and detailed comparative assessment of product offerings and strategies of key providers specific to the market segments. Detailed profiles of players operating in the global anticancer drugs market are also provided in the report, which highlight company description, overview, product/segment overview, SWOT analysis, financial information, key developments related to market and strategic overview.

The next section of report analyzes the anticancer drugs market based on drug class and presents the forecast in terms of value for the next 8 years. The drug class covered in the report include:

Cytotoxic
Hormonal Therapy
Targeted Therapy
Monoclonal antibodies
Small molecule inhibitors

The targeted therapy segment is expected to be the largest segment in the global anticancer drugs market by drug class. The targeted therapy segment is followed by cytotoxic segment which has been the traditional treatment for cancer. The attractive advantages of targeted therapy such as greater selectivity, efficacy and effectiveness confers faster cure rates concurrent with lower side effects, which is the holy grail of anticancer drugs market.

The next section of report analyzes the anticancer drugs market based on distribution channel for anticancer drugs products and provides forecast in terms of value for the next 8 years. The distribution channels covered in the report include:

Hospital Pharmacies
Retail Pharmacies

Another key feature of this report is the analysis of the key segments in terms of absolute dollar opportunity. This is traditionally overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective of the products. To understand the key growth segments, Persistence Market Research provides the ‘Attractiveness Index’ analysis, which helps to identify the real market opportunities.

  • Table 1A : Funding by Research Areas 2017 (US $Millions)
  • Table 1A : Funding by Research Areas 2017 (US $Millions)
  • Table 1B : Funding by Research Areas 2017 (US $Millions)
  • Table 2A : New Active Substances Launched in 2017 and Summary of Clinical Benefits
  • Table 2B : New Active Substances Launched in 2017 and Summary of Clinical Benefits
  • Table 2C : New Active Substances Launched in 2017 and Summary of Clinical Benefits
  • Table 3 : Estimated Number of Deaths for the Four Major Cancers by Sex and Age Group, 2017
  • Table 4 : Estimated New Cases for the Four Major Cancers by Sex and Age Group, 2016
  • Table 5 : Difference in approval times between EMEA and FDA for selected targeted therapies
  • Table 6 : Expenditure on Health, (% of GDP), by Country, 2016 - 2021
  • Table 7 : Expenditure on Health, (% of GDP), by Country, 2016 - 2021
  • Table 8A : Prevalence of Cancer in North America, 2017
  • Table 8B : Prevalence of Cancer in Latin America, 2017
  • Table 8C : Prevalence of Cancer in Asia Pacific, 2017
  • Table 8D : Prevalence of Cancer in Europe, 2017
  • Table 9 : Number of FDA Approvals (2010-2017)
  • Table 10 : North America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
  • Table 11 : North America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
  • Table 12 : North America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication
  • Table 13 : North America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
  • Table 14 : North America Anticancer Drugs Market Participants Presence (Intensity Mapping)
  • Table 15 : Latin America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
  • Table 16 : Latin America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
  • Table 17 : Latin America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication
  • Table 18 : Latin America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
  • Table 19 : North America Anticancer Drugs Market Participants Presence (Intensity Mapping)
  • Table 20 : Europe Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
  • Table 21 : Europe Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
  • Table 22 : Europe Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication
  • Table 23 : Europe Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
  • Table 24 : Europe Anticancer Drugs Market Participants Presence (Intensity Mapping)
  • Table 25 : Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
  • Table 26 : Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
  • Table 27 : Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication
  • Table 28 : Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
  • Table 29 : Asia Pacific Excluding Japan Anticancer Drugs Market Participants Presence (Intensity Mapping)
  • Table 30 : Japan Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
  • Table 31 : Japan Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication
  • Table 32 : Japan Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
  • Table 33 : Japan Anticancer Drugs Market Participants Presence (Intensity Mapping)
  • Table 34 : Middle East and Africa Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
  • Table 35 : Middle East and Africa Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
  • Table 36 : Middle East and Africa Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication
  • Table 37 : Middle East and Africa Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
  • Table 38 : Middle East and Africa Anticancer Drugs Market Participants Presence (Intensity Mapping)
  • Table 39A : Competition Dashboard
  • Table 39B : Competition Dashboard
  • Table 39C : Competition Dashboard
  • Table 40 : Anticancer Drugs Market Value (US$ Mn) 2013�2017 and Forecast 2018-2026 By Region
  • Table 41 : Global Anticancer Drugs Market Value Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
  • Table 42 : Global Anticancer Drugs Market Value Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indications
  • Table 43 : Global Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channels
  • Figure 1 : Global Anticancer Drugs Market Value Share By Drug Class (2018 E)
  • Figure 2 : Global Anticancer Drugs Market Value Share By Indications (2018 E)
  • Figure 3 : Global Anticancer Drugs Market Value Share By Distribution Channel (2018 E)
  • Figure 4 : Global Anticancer Drugs Market Value Share By Regions (2018 E)
  • Figure 5 : New Cancer Drugs Approved Each Year
  • Figure 6 : Growth of the Late Phase Oncology Pipeline, 2005-2015
  • Figure 7 : The Global Late Phase Oncology Pipeline in 2015
  • Figure 8 : Estimates Of National Expenditures For Cancer Care (In Billions Of Dollars) By Cancer Site And Year
  • Figure 9 : Availability of 55 Oncology Medicines First Launched Globally 2012�2016
  • Figure 10 : Number of FDA approved pharmaceuticals (2010-2017)
  • Figure 11 : North America Anticancer Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 12 : North America Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 13 : Canada Anticancer Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 14 : U.S. Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 15 : Canada Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 16 : U.S. Anticancer Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 17 : Hormonal Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 18 : Cytotoxics Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 19 : Hormonal Therapy Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 20 : Cytotoxics Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 21 : Targeted Therapy Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 22 : Targeted Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 23 : North America Anticancer Drugs Market Attractiveness Analysis By Country, 2018-2026
  • Figure 24 : North America Anticancer Drugs Market Attractiveness Analysis By Indication, 2018-2026 (US$ Mn)
  • Figure 25 : North America Anticancer Drugs Market Attractiveness Analysis By Distribution Channel, 2018-2026
  • Figure 26 : North America Anticancer Drugs Market Attractiveness Analysis By Drug Class, 2018-2026
  • Figure 27 : Latin Anticancer Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 28 : Latin Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 29 : Mexico Anticancer Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 30 : Brazil Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 31 : Mexico Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 32 : Brazil Anticancer Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 33 : Rest of Latin America Anticancer Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 34 : Rest of Latin America Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 35 : Hormonal Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 36 : Cytotoxics Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 37 : Hormonal Therapy Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 38 : Cytotoxics Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 39 : Targeted Therapy Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 40 : Targeted Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 41 : Latin America Anticancer Drugs Market Attractiveness Analysis By Country, 2018-2026
  • Figure 42 : Latin America Anticancer Drugs Market Attractiveness Analysis By Indication, 2018-2026
  • Figure 43 : Latin America Anticancer Drugs Market Attractiveness Analysis By Distribution Channel, 2018-2026
  • Figure 44 : Latin America Anticancer Drugs Market Attractiveness Analysis By Drug Class, 2018-2026
  • Figure 45 : Europe Anticancer Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 46 : Europe Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 47 : Germany Anticancer Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 48 : U.K. Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 49 : Germany Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 50 : U.K. Anticancer Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 51 : Italy Anticancer Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 52 : France Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 53 : Italy Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 54 : France Anticancer Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 55 : Russia Anticancer Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 56 : Spain Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 57 : Russia Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 58 : Spain Anticancer Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 59 : Rest of Europe Anticancer Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 60 : Rest of Europe Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 61 : Hormonal Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 62 : Cytotoxics Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 63 : Hormonal Therapy Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 64 : Cytotoxics Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 65 : Targeted Therapy Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 66 : Targeted Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 67 : Europe Anticancer Drugs Market Attractiveness Analysis By Country, 2018-2026
  • Figure 68 : Europe Anticancer Drugs Market Attractiveness Analysis By Indication, 2018-2026
  • Figure 69 : Europe Anticancer Drugs Market Attractiveness Analysis By Distribution Channel, 2018-2026
  • Figure 70 : Europe Anticancer Drugs Market Attractiveness Analysis By Drug Class, 2018-2026
  • Figure 71 : Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 72 : Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 73 : India Anticancer Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 74 : China Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 75 : India Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 76 : China Anticancer Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 77 : ASEAN Anticancer Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 78 : Australia and NZ Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 79 : ASEAN Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 80 : Australia and NZ Anticancer Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 81 : Rest of Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 82 : Rest of Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 83 : Hormonal Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 84 : Cytotoxics Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 85 : Hormonal Therapy Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 86 : Cytotoxics Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 87 : Targeted Therapy Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 88 : Targeted Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 89 : Asia Pacific Excluding Japan Anticancer Drugs Market Attractiveness Analysis By Country, 2018-2026
  • Figure 90 : Asia Pacific Excluding Japan Anticancer Drugs Market Attractiveness Analysis By Indication, 2018-2026
  • Figure 91 : Asia Pacific Excluding Japan Anticancer Drugs Market Attractiveness Analysis By Distribution Channel, 2018-2026
  • Figure 92 : Asia Pacific Excluding Japan Anticancer Drugs Market Attractiveness Analysis By Drug Class, 2018-2026
  • Figure 93 : Japan Anticancer Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 94 : Japan Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 95 : Hormonal Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 96 : Cytotoxics Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 97 : Hormonal Therapy Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 98 : Cytotoxics Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 99 : Targeted Therapy Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 100 : Targeted Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 101 : Japan Anticancer Drugs Market Attractiveness Analysis By Drug Class, 2018-2026
  • Figure 102 : Japan Anticancer Drugs Market Attractiveness Analysis By Indication, 2018-2026 (US$ Mn)
  • Figure 103 : Japan Anticancer Drugs Market Attractiveness Analysis By Distribution Channel, 2018-2026
  • Figure 104 : Middle East and Africa Anticancer Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 105 : Middle East and Africa Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 106 : GCC Countries Anticancer Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 107 : South Africa Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 108 : GCC Countries Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 109 : South Africa Anticancer Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 110 : Rest of Middle East and Africa Anticancer Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 111 : Rest of Middle East and Africa Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 112 : Hormonal Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 113 : Cytotoxics Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 114 : Hormonal Therapy Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 115 : Cytotoxics Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 116 : Targeted Therapy Drugs Market Value (US$ Mn) Analysis, 2013�2017
  • Figure 117 : Targeted Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018�2026
  • Figure 118 : Middle East and Africa Anticancer Drugs Market Attractiveness Analysis By Country, 2018-2026
  • Figure 119 : Middle East and Africa Anticancer Drugs Market Attractiveness Analysis By Indication, 2018-2026
  • Figure 120 : Middle East and Africa Anticancer Drugs Market Attractiveness Analysis By Distribution Channel, 2018-2026
  • Figure 121 : Middle East and Africa Anticancer Drugs Market Attractiveness Analysis By Drug Class, 2018-2026
  • Figure 122 : Revenue Contribution by Tier Type
  • Figure 123 : Global Anticancer Drugs Market Structure
  • Figure 124 : Global Anticancer Drugs Market Share Analysis (%) By Region, 2018 & 2026
  • Figure 125 : Global Anticancer Drugs Market Y-o-Y Growth (%) By Region, 2017�2026
  • Figure 126 : Global Anticancer Drugs Market Attractiveness Analysis By Region, 2018�2026
  • Figure 127 : Global Anticancer Drugs Market Share
  • Figure 128 : Anticancer Drugs Market Y-o-Y Growth (%) By Drug Class, 2017�2026
  • Figure 129 : Global Anticancer Drugs Market Attractiveness Analysis By Drug Class, 2018�2026
  • Figure 130 : Global Anticancer Drugs Market Share
  • Figure 131 : Anticancer Drugs Market Y-o-Y Growth (%) By Indications, 2017�2026
  • Figure 132 : Global Anticancer Drugs Market Attractiveness Analysis By Indications, 2018�2026
  • Figure 133 : Global Anticancer Drugs Market Share Analysis (%) By Distribution Channels, 2018 & 2026
  • Figure 134 : Global Anticancer Drugs Market
  • Figure 135 : Global Anticancer Drugs Market Attractiveness Analysis By Distribution Channels, 2018�2026
  • Figure 136 : Global Anticancer Drugs Market Value Analysis and Forecast, 2017�2026 (US$ Mn)
  • Figure 137 : Global Anticancer Drugs Market Absolute $ Opportunity (US$ Mn), 2017�2026

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organization of all sizes.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report